Advertisement

Endocrine Pathology

, Volume 23, Issue 2, pp 115–122 | Cite as

Occult Primary Medullary Thyroid Carcinoma Presenting with Pituitary and Parotid Metastases: Case Report and Review of the Literature

  • Andrea Conway
  • Andres Wiernik
  • Ajay Rawal
  • Cornelius Lam
  • Hector Mesa
Article

Introduction

Medullary thyroid carcinoma (MTC) accounts for <10% of all thyroid malignancies and is derived from the calcitonin-producing C cell [1, 2]. It is of particular interest because of its association with hereditary syndromes, aggressiveness, and refractoriness to adjuvant therapies, and its association with mutations in the RET (rearranged during transfection) proto-oncogene, which encodes a receptor tyrosine kinase that may be amenable to therapy with the recently available tyrosine kinase inhibitors (TKI) [3, 4]. Thyroid tumors metastasizing to the pituitary and parotid gland are rare, and medullary thyroid carcinoma metastatic to either site has only been reported in a handful of instances. Here, we report a rare case of an occult MTC, which presented with clinical symptoms associated with synchronous metastases to the pituitary and parotid gland, and discuss its differential diagnosis.

Case Report

A 61-year-old man with no significant past medical problems presented to...

Keywords

Pituitary Adenoma Parotid Gland Diabetes Insipidus Medullary Thyroid Carcinoma Vandetanib 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Wells SA, Franz C. Medullary carcinoma of the thyroid gland. World J Surg 24:952-956, 2000.PubMedCrossRefGoogle Scholar
  2. 2.
    Mills, Stacy E. Pathology of the thyroid and parathyroid disease. In: Sternberg’s Diagnostic Surgical Pathology. 6th ed.Google Scholar
  3. 3.
    Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. JAMA 276(19):1575-1579, 1996.PubMedCrossRefGoogle Scholar
  4. 4.
    Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol 61:299–310, 2004.CrossRefGoogle Scholar
  5. 5.
    DeLellis R.A., Lloyd R.V., Heitz, P.U., Eng C. (Eds.): World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. IARC Press: Lyon 2004; 86–91.Google Scholar
  6. 6.
    Grozinsky-Glasberg S, Benbassat CA, Tsvetov G, Feinmesser R, Peretz H, Shimon I, Lapidot M. Medullary thyroid cancer: a retrospective analysis of a cohort treated at a single tertiary care center between 1970 and 2005. Thyroid 17(6):549–556, 2007.PubMedCrossRefGoogle Scholar
  7. 7.
    Scollo C, Baudin E, Travagli JP, Caillou B, Bellon N, Leboulleux S, Schlumberger M. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88(5):2070–2075, 2003.PubMedCrossRefGoogle Scholar
  8. 8.
    Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 229(6):880–888, 1999.PubMedCrossRefGoogle Scholar
  9. 9.
    Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6):319–42, 1984.Google Scholar
  10. 10.
    Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 31(10):1960–1965, 2007.PubMedCrossRefGoogle Scholar
  11. 11.
    Quayle FJ, Moley JF. Medullary thyroid carcinoma: including MEN2A and 2B syndromes. J Surg Oncol 89:122–129, 2005.PubMedCrossRefGoogle Scholar
  12. 12.
    Chen H, Sipper RS, O’Dorisio MS, Vinik Al, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 39(6):775–783, 2010.PubMedCrossRefGoogle Scholar
  13. 13.
    Albores-Saavedra J, LiVolsi VA, Williams ED. Medullary carcinoma. Semin Diagn Pathol 2:137–146, 1985.PubMedGoogle Scholar
  14. 14.
    Sironi M, Cozzi L, Pareschi R, Spreafic GL, Assi A. Occult sporadic medullary microcarcinoma with lymph node metastases. Diagn Cytopathol 21(3):203–206, 1999.PubMedCrossRefGoogle Scholar
  15. 15.
    Beressi N, Campos JM, Beressi JP, Franc B, Niccoli-Sire P, Conte-Devolx B, Murat A, Caron P, Baldet L, Kraimps JL, Cohen R, Bigorgne JC, Chabre O, Lecomte P, Modigliani E. Thyroid. Sporadic medullary microcarcinoma of the thyroid: a retrospective analysis of eighty cases. Thyroid 8(11):1039–1044, 1998.PubMedCrossRefGoogle Scholar
  16. 16.
    Fassett DR, Couldwell WT. Metastasis to the pituitary gland. Neurosurg Focus 16(4):E8, 2004.PubMedGoogle Scholar
  17. 17.
    Teears RJ, Silverman EM. Clinicopathologic review of 88 cases of carcinoma metastatic to the pituitary gland. Cancer 36:216–220, 1975.PubMedCrossRefGoogle Scholar
  18. 18.
    Asa SL. Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 132:1231–1240, 2008.PubMedGoogle Scholar
  19. 19.
    Morita A, Meyer FB, Laws ER Jr. Symptomatic pituitary metastases. J Neurosurg 89: 69–73, 1998.PubMedCrossRefGoogle Scholar
  20. 20.
    Roessmann U, Kaufman B, and Friede RL. Metastatic lesions in the sella turcica and pituitary gland. Cancer 25:478–480, 1970.PubMedCrossRefGoogle Scholar
  21. 21.
    Bhatoe HS, Badwal S, Dutta V, Kannan N. Pituitary metastasis from medullary carcinoma of thyroid: case report and review of literature. J Neurooncol 89:63–67, 2008.PubMedCrossRefGoogle Scholar
  22. 22.
    Santarpia L, Gagel RF, Sherman SI, Sarlis NJ, Evans DB, Hoff AO. Diabetes insipidus and panhypopituitarism due to intrasellar metastasis from medullary thyroid cancer. Head Neck 31(3): 419–423, 2009.PubMedCrossRefGoogle Scholar
  23. 23.
    Batsakis JG. Pathology consultation. Parotid gland and its lymph nodes as metastatic sites. Ann Otol Rhinol Laryngol 92:209–210, 1983.PubMedGoogle Scholar
  24. 24.
    Nuyens M, Schüpbach J, Stauffer E, Zbären P. Metastatic disease to the parotid gland. Otolaryngol Head Neck Surg 135:844–848, 2006.PubMedCrossRefGoogle Scholar
  25. 25.
    Mohyuddin H, Mahrous A, Sharma V, Gluckman P. Parotid mass: an unusual presentation of gastroesophageal malignancy. J Laryngol Otol 125(5):546–548, 2011.PubMedCrossRefGoogle Scholar
  26. 26.
    Ulubas B, Ozcan C, Polat A. Small cell lung cancer diagnosed with metastasis in parotid gland. J Craniofac Surg 21(3):781–783, 2010.PubMedCrossRefGoogle Scholar
  27. 27.
    Moutaouakil A, Baha AT, and Amraoui A. Metastase choroidienne d’un carcinome de la thyroide (a propos d’un cas). Bull Soc Belge Ophtalmol 288:19–22, 2003.PubMedGoogle Scholar
  28. 28.
    Pelosi S, Genden EM. Medullary thyroid carcinoma metastatic to the parotid gland. The Laryngoscope (Meeting Abstracts) 119(Supplement S3):S253, 2009.Google Scholar
  29. 29.
    Ebert EC. The thyroid and the gut. J Clin Gastroenterol 44:402–406, 2010.PubMedGoogle Scholar
  30. 30.
    Krafts KP, Pambuccian SE. Romanowsky staining in cytopathology: history, advantages and limitations. Biotech Histochem 86(2):82–93, 2011.PubMedCrossRefGoogle Scholar
  31. 31.
    Agoff SN, Lamps LW, Philip AT, Amin MB, Schmidt RA, True LD, Folpe AL. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol 13(3):238–242, 2000.PubMedCrossRefGoogle Scholar
  32. 32.
    Nonaka D, Tang Y, Chiriboga L, Rivera M, Ghossein R. Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Mod Pathol 21:192–200, 2008.PubMedGoogle Scholar
  33. 33.
    Mills SE. Neuroectodermal neoplasms of the head and neck with emphasis on neuroendocrine carcinomas. Mod Pathol 15(3):264–278, 2002.PubMedCrossRefGoogle Scholar
  34. 34.
    Wenig BM, Hyams VJ, Heffner DK. Moderately differentiated neuroendocrine carcinoma of the larynx. A clinicopathologic study of 54 cases. Cancer 62:2658–2676, 1988.PubMedCrossRefGoogle Scholar
  35. 35.
    Machens A, Haedecke J, Hinze R, Thomusch O, Schneyer U, Dralle H. Hypercalcitoninemia in a sporadic asymptomatic neuroendocrine tumor of the pancreatic tail. Dig Surg 17(5):522–4, 2000.PubMedCrossRefGoogle Scholar
  36. 36.
    Alapat DV, Ain KB, Sloan DA, Monaghan KG, Karabakhtsian RG. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma. Endocrine 39(2):148-52, 2011.PubMedCrossRefGoogle Scholar
  37. 37.
    Leboulleux S, Baudin E, Young J, Caillou B, Lazar V, Pellegriti G, Ducreux M, Schaison G, Schlumberger M. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140:187–191, 1999.PubMedCrossRefGoogle Scholar
  38. 38.
    Milione M, Seregni E. Pathological diagnosis and tumor markers. Tumori 96: 810–816, 2010.PubMedGoogle Scholar
  39. 39.
    Bajetta E, Ferrari L,Martinetti A, Celio L, Procopio G, Artale S, Zilembo N, Di Bartolomeo M, Seregni E, Bombardieri E. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 86: 858–865, 1999.PubMedCrossRefGoogle Scholar
  40. 40.
    Rosai and Ackerman’s Surgical Pathology, 10th edn; 48, 329–330, 526–531, 822–840.Google Scholar
  41. 41.
    Su CH, Chang H, Chen CJ, Liu LC, Wang HC, Lane HY, Bau DT. The carcinoembryonic antigen as a potential prognostic marker for neuroendocrine carcinoma of the breast. Anticancer Res 32(1):183–188, 2012.PubMedGoogle Scholar
  42. 42.
    Kleinschmidt–DeMasters. Pituitary Gland. In: Rosai and Ackerman’s Surgical Pathology, 10th edn.Google Scholar
  43. 43.
    Coons SW, Etrada SI, Gamez R, White WL. Cytokeratin CK7 and CK 20 expression in pituitary adenomas. Endocr Pathol 16: 201–210, 2005.PubMedCrossRefGoogle Scholar
  44. 44.
    Lee EB, Tihan T, Scheithauer BW, Zhang PJ, Gonatas NK. Thyroid transcription factor 1 expression in sellar tumors: a histogenetic marker?. JNEN 68(5):482–8, 2009.Google Scholar
  45. 45.
    Takei H, Goodman JC, Tanaka S, Bhattacharjee MB, Bahrami A Powell, SZ. Pituicytoma incidentally found at autopsy. Pathol Int 55:745–749, 2005.PubMedCrossRefGoogle Scholar
  46. 46.
    Salame K, Ouaknine GE, Yossipov J, Rochkind S. Paraganglioma of the pituitary fossa: diagnosis and management. J Neurooncol 54(1):49–52, 2001.PubMedCrossRefGoogle Scholar
  47. 47.
    McLaughlin DM, Gray WJ, Jones FG, Mirakhur M, McCance DR, Sheridan B, Atkinson AB. Plasmacytoma: an unusual cause of a pituitary mass lesion. A case report and a review of the literature. Pituitary 7(3):179–81, 2004.PubMedCrossRefGoogle Scholar
  48. 48.
    Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Ny Tovo N, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli JP, Baudin E and Schlumberger M. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 92(11):4185–4190, 2007.PubMedCrossRefGoogle Scholar
  49. 49.
    Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63(6):319–342, 1984.Google Scholar
  50. 50.
    O’Riordain DS, O’Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116(6):1017–1023, 1994.PubMedGoogle Scholar
  51. 51.
    Kebebew E, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 88(5):1139–1148, 2000.PubMedCrossRefGoogle Scholar
  52. 52.
    Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 67(4):801–805, 1988.PubMedCrossRefGoogle Scholar
  53. 53.
    Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6(4):305–310, 1996.PubMedCrossRefGoogle Scholar
  54. 54.
    Nocera M, Baudin E, Pellegriti G, Cailleux AF, Mechelany-Corone C, Schlumberger M. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC). Br J Cancer 83(6):715–718, 2000.PubMedCrossRefGoogle Scholar
  55. 55.
    Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP 3rd. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 73(2):432–436, 1994.PubMedCrossRefGoogle Scholar
  56. 56.
    Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 104(7):1067–1070, 2011.PubMedCrossRefGoogle Scholar
  57. 57.
    Fürstenberger G, Schmid P, Duquesne A, Ammann M, Senn HJ. Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda) monotherapy. Cancer Chemother Pharmacol 61(2):347–348, 2008.PubMedCrossRefGoogle Scholar
  58. 58.
    Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24(3):401–406, 2006.PubMedCrossRefGoogle Scholar
  59. 59.
    Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B.Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13(10):2986–2991, 2007.PubMedCrossRefGoogle Scholar
  60. 60.
    R. L. Fine, D. R. Fogelman, S. M. Schreibman. Effective Treatment of Neuroendocrine Tumors With Temozolomide and Capecitabine. Journal of Clinical Oncology (Meeting Abstracts) 23(Suppl 16S):4216, 2005.Google Scholar
  61. 61.
    Paiva CE, Michelin OC. Use of capecitabine in refractory metastatic medullary thyroid carcinoma. Thyroid 18(5):587, 2008.PubMedCrossRefGoogle Scholar
  62. 62.
    Gilliam LK, Kohn AD, Lalani T, Swanson PE, Vasko V, Patel A, Livingston RB, Pickett CA.Capecitabine therapy for refractory metastatic thyroid carcinoma: a case series. Thyroid 16(8):801–810, 2006.PubMedCrossRefGoogle Scholar
  63. 63.
    Labidi SI, Gravis G, Tarpin C, Brun V, Viens P. Medullary thyroid cancer treated by capecitabine. Anticancer Drugs 18(7):831–834, 2007.PubMedCrossRefGoogle Scholar
  64. 64.
    Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr Opin Oncol 22(4):381–386, 2010.PubMedCrossRefGoogle Scholar
  65. 65.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5):646–74, 2011.PubMedCrossRefGoogle Scholar
  66. 66.
    Zhang J, Yang PL, Gray NS.Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9(1):28–39, 2009.PubMedCrossRefGoogle Scholar
  67. 67.
    Spector E, Franklin MJ, Truskinovsky AM, Dudek AZ. Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta Oncol 49(1):104–106, 2010.PubMedCrossRefGoogle Scholar
  68. 68.
    Lam ET, Ringel MD, Kloos RT, Prior TW, Knopp MV, Liang J, Sammet S, Hall NC, Wakely PE Jr, Vasko VV, Saji M, Snyder PJ, Wei L, Arbogast D, Collamore M, Wright JJ, Moley JF, Villalona-Calero MA, Shah MH. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28(14):2323–2330, 2010.PubMedCrossRefGoogle Scholar
  69. 69.
    Cohen, EEW, Needles, BM, Cullen, KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (Meeting Abstracts) 26:6025, 2008.Google Scholar
  70. 70.
    Ravaud, A, de la Fouchardière, C, Courbon, F, et al. Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial. J Clin Oncol (Meeting Abstracts) 26:6058, 2008.CrossRefGoogle Scholar
  71. 71.
    Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27(23):3794–801, 2009.PubMedCrossRefGoogle Scholar
  72. 72.
    Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28(5):767–72, 2010.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2012

Authors and Affiliations

  • Andrea Conway
    • 1
  • Andres Wiernik
    • 2
  • Ajay Rawal
    • 3
  • Cornelius Lam
    • 4
  • Hector Mesa
    • 3
  1. 1.Department of PathologyUniversity of MinnesotaMinneapolisUSA
  2. 2.Hematology-Oncology SectionUniversity of MinnesotaMinneapolisUSA
  3. 3.Department of PathologyVeterans Administration Health Care SystemMinneapolisUSA
  4. 4.Department of NeurosurgeryUniversity of MinnesotaMinneapolisUSA

Personalised recommendations